R6890

Spirochlorphine
Clinical data
Other namesSpirochlorphine
Identifiers
  • 8-[1-(4-chlorophenyl)ethyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC21H24ClN3O
Molar mass369.89 g·mol−1
3D model (JSmol)
  • CC(C1=CC=C(C=C1)Cl)N2CCC3(CC2)C(=O)NCN3C4=CC=CC=C4
  • InChI=1S/C21H24ClN3O/c1-16(17-7-9-18(22)10-8-17)24-13-11-21(12-14-24)20(26)23-15-25(21)19-5-3-2-4-6-19/h2-10,16H,11-15H2,1H3,(H,23,26)
  • Key:KFEYPBZJPJJRFX-UHFFFAOYSA-N

R6890, sometimes known as spirochlorphine, is an orphine opioid analgesic and a member of the spiropiperidine family of agents. The first known mention of this compound was in 1977. Other examples of agents from this class are Ro64-6198 and Ro65-6570. Brorphine also has a similar structure. It has been sold as a designer drug, and was proposed for placement on the Schedule 1 list in the USA on 1 July 2026. Spirochlorphine is a Schedule V controlled substance in Canada.

A precursor chemical used in the synthesis of R6890 is 1-phenyl-1,3,8-triazaspiro(4,5)decan-4-one (also known as spirodecanone), which is used in the synthesis of other drugs including spirilene, fluspirilene, spiramide, spiperone, RP-23618, spiroxatrine, L008716 and R5260.

Pharmacology

The pharmacology of R6890 is described as a nociceptin receptor (NOP) agonist, although R6890 retains significant affinity at the mu opioid receptor in an animal model. R6890 has affinities (Ki values) of 4, 75, and 10 nM for the mu, delta, and the total opioid receptor population, respectively.

See also